PMID- 11386264
OWN - NLM
STAT- MEDLINE
DCOM- 20010607
LR  - 20220408
IS  - 0028-4793 (Print)
IS  - 0028-4793 (Linking)
VI  - 344
IP  - 22
DP  - 2001 May 31
TI  - A trial of the beta-blocker bucindolol in patients with advanced chronic heart 
      failure.
PG  - 1659-67
AB  - BACKGROUND: Although beta-adrenergic-receptor antagonists reduce morbidity and 
      mortality in patients with mild-to-moderate chronic heart failure, their effect 
      on survival in patients with more advanced heart failure is unknown. METHODS: A 
      total of 2708 patients with heart failure designated as New York Heart 
      Association (NYHA) functional class III (in 92 percent of the patients) or IV (in 
      8 percent) and a left ventricular ejection fraction of 35 percent or lower were 
      randomly assigned to double-blind treatment with either bucindolol (1354 
      patients) or placebo (1354 patients) and followed for the primary end point of 
      death from any cause. RESULTS: The data and safety monitoring board recommended 
      stopping the trial after the seventh interim analysis. At that time, there was no 
      significant difference in mortality between the two groups (unadjusted P=0.16). 
      The results presented here are based on complete follow-up at the time of study 
      termination (average, 2.0 years). There were a total of 449 deaths in the placebo 
      group (33 percent) and 411 deaths in the bucindolol group (30 percent; adjusted 
      P=0.13). The risk of the secondary end point of death from cardiovascular causes 
      was lower in the bucindolol group (hazard ratio, 0.86; 95 percent confidence 
      interval, 0.74 to 0.99), as was the risk of heart transplantation or death 
      (hazard ratio, 0.87; 95 percent confidence interval, 0.77 to 0.99). CONCLUSIONS: 
      In a demographically diverse group of patients with NYHA class III and IV heart 
      failure, bucindolol resulted in no significant overall survival benefit.
CN  - Beta-Blocker Evaluation of Survival Trial Investigators
FAU - Eichhorn, Eric J
AU  - Eichhorn EJ
FAU - Domanski, Michael J
AU  - Domanski MJ
FAU - Krause-Steinrauf, Heidi
AU  - Krause-Steinrauf H
FAU - Bristow, Michael R
AU  - Bristow MR
FAU - Lavori, Philip W
AU  - Lavori PW
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Propanolamines)
RN  - E9UO06K7CE (bucindolol)
SB  - IM
CIN - ACP J Club. 2001 Nov-Dec;135(3):84
CIN - N Engl J Med. 2001 May 31;344(22):1711-2. PMID: 11386271
CIN - N Engl J Med. 2001 Sep 27;345(13):998; author reply 998-9. PMID: 11575300
MH  - Adrenergic beta-Antagonists/adverse effects/*therapeutic use
MH  - Aged
MH  - Chronic Disease
MH  - Double-Blind Method
MH  - Female
MH  - Heart Failure/classification/*drug therapy/ethnology/mortality
MH  - Heart Transplantation/statistics & numerical data
MH  - Hospitalization/statistics & numerical data
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Propanolamines/adverse effects/*therapeutic use
MH  - Proportional Hazards Models
MH  - Severity of Illness Index
MH  - Survival Analysis
EDAT- 2001/06/02 10:00
MHDA- 2001/06/08 10:01
CRDT- 2001/06/02 10:00
PHST- 2001/06/02 10:00 [pubmed]
PHST- 2001/06/08 10:01 [medline]
PHST- 2001/06/02 10:00 [entrez]
AID - 10.1056/NEJM200105313442202 [doi]
PST - ppublish
SO  - N Engl J Med. 2001 May 31;344(22):1659-67. doi: 10.1056/NEJM200105313442202.